About Ataxin-10
Ataxin-10 (ATXN10) is a protein
from Homo sapiens identified by UniProt accession
Q9UBB4, 475 residues long.
MolForge cross-references it against 0 known binders and
90 disease associations.
Target properties
| Protein name | Ataxin-10 |
|---|
| UniProt accession | Q9UBB4 |
|---|
| Gene | ATXN10 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 475 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (90)
Diseases linked to this target (Open Targets).
- spinocerebellar ataxia type 10 · score 0.64
- neurodegenerative disease · score 0.44
- IGF-1 measurement · score 0.29
- body height · score 0.28
- cortical surface area measurement · score 0.28
- heel bone mineral density · score 0.26
- hematocrit · score 0.26
- hemoglobin measurement · score 0.25
- erythrocyte count · score 0.25
- adolescent idiopathic scoliosis · score 0.22
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9UBB4-F1 | alphafold | PREDICTED | 89.54 | — |
Amino-acid sequence (475 residues)
MAAPRPPPAR LSGVMVPAPI QDLEALRALT ALFKEQRNRE TAPRTIFQRV LDILKKSSHA VELACRDPSQ VENLASSLQL ITECFRCLRN ACIECSVNQN SIRNLDTIGV AVDLILLFRE LRVEQESLLT AFRCGLQFLG NIASRNEDSQ SIVWVHAFPE LFLSCLNHPD KKIVAYSSMI LFTSLNHERM KELEENLNIA IDVIDAYQKH PESEWPFLII TDLFLKSPEL VQAMFPKLNN QERVTLLDLM IAKITSDEPL TKDDIPVFLR HAELIASTFV DQCKTVLKLA SEEPPDDEEA LATIRLLDVL CEMTVNTELL GYLQVFPGLL ERVIDLLRVI HVAGKETTNI FSNCGCVRAE GDISNVANGF KSHLIRLIGN LCYKNKDNQD KVNELDGIPL ILDNCNISDS NPFLTQWVIY AIRNLTEDNS QNQDLIAKME EQGLADASLL KKVGFEVEKK GEKLILKSTR DTPKP
Explore Ataxin-10 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets